Castle Creek Biosciences chair Jeff Aronin
Scoop: After pulling IPO ambitions last December, Jeff Aronin's Castle Creek turns to private backers
Jeff Aronin’s cell and gene therapy biotech Castle Creek Biosciences has raised $112 million in equity, Endpoints News has learned.
The Exton, PA, biotech secured …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
